Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
1. Inclusion Criteria:~   1. Clinical symptoms: -presence of chronic pulmonary/systemic symptoms lasting ≥ six weeks.~  2. Radiological findings:~      * Evidence of slowly progressive pulmonary lesions over weeks-months including cavities with surrounding inflammation.~     * presence of intracavitary mass with a surrounding crescent of air,and presence of pleural thickening in peripheral lesions.~  3. Microbiological/Immunological findings: Positive results in the aspergillus precipitin test, demonstration of aspergillus hyphae in sputum or BAL fluid or cultures of BAL/sputum growing aspergillus species.~2. The diagnosis of CCPA will be made if~   1. Patient satisfies at least 1, 2a or 2b and/ or any of the 3rd criteria.~  2. FNAC from the cavity wall will be considered in atypical cases~3. Exclusion Criteria:~   1. Invasive aspergillosis~  2. Allergic broncho-pulmonary aspergillosis (ABPA)~  3. Active tuberculosis or malignancy~  4. Pregnant females

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Itraconazole (Type: ACTIVE_COMPARATOR): Role of itraconazole in CCPA
- treatment in cavitary pulmonary aspergillosis (Type: EXPERIMENTAL): Patients in this arm are given conservative management with antitussives, brochial artery embolisation.

Based on this trial design, predict the completion outcome and termination type (if applicable).